BioVaxys Technology (FRA:5LB0) LT-Debt-to-Total-Asset: 0.00 (As of Jul. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is BioVaxys Technology LT-Debt-to-Total-Asset?

BioVaxys Technology FRA:5LB0 LT-Debt-to-Total-Asset is 0.00 as of Jul. 2025.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. BioVaxys Technology's long-term debt to total assests ratio for the quarter that ended in Jul. 2025 was 0.00.

BioVaxys Technology's long-term debt to total assets ratio stayed the same from Jul. 2024 (0.00) to Jul. 2025 (0.00).

BioVaxys Technology  (FRA:5LB0) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

BioVaxys Technology LT-Debt-to-Total-Asset Related Terms

BioVaxys Technology LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for BioVaxys Technology's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioVaxys Technology LT-Debt-to-Total-Asset Chart

BioVaxys Technology Annual Data
Trend Oct18 Oct19 Oct20 Oct21 Oct22 Oct23 Oct24
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

BioVaxys Technology Quarterly Data
Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

BioVaxys Technology LT-Debt-to-Total-Asset Calculation

BioVaxys Technology's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Oct. 2024 is calculated as

LT Debt to Total Assets (A: Oct. 2024 )=Long-Term Debt & Capital Lease Obligation (A: Oct. 2024 )/Total Assets (A: Oct. 2024 )
=0/0.868
=

BioVaxys Technology's Long-Term Debt to Total Asset Ratio for the quarter that ended in Jul. 2025 is calculated as

LT Debt to Total Assets (Q: Jul. 2025 )=Long-Term Debt & Capital Lease Obligation (Q: Jul. 2025 )/Total Assets (Q: Jul. 2025 )
=0/0.868
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →
What does a LT-Debt-to-Total-Asset of 0.00 mean?
BioVaxys Technology (FRA:5LB0) has a LT-Debt-to-Total-Asset of 0.00 as of Jul. 2025. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on BioVaxys Technology and its competitors.
Is BioVaxys Technology's LT-Debt-to-Total-Asset too high?
BioVaxys Technology's current LT-Debt-to-Total-Asset is 0.00.
How does BioVaxys Technology's LT-Debt-to-Total-Asset compare to BPTH and AZTR?
BioVaxys Technology's LT-Debt-to-Total-Asset of 0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good LT-Debt-to-Total-Asset for a Biotechnology company?
A good LT-Debt-to-Total-Asset depends on the Biotechnology industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high LT-Debt-to-Total-Asset mean?
A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on BioVaxys Technology and its competitors. BioVaxys Technology's current LT-Debt-to-Total-Asset is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioVaxys Technology stock overvalued right now?
BioVaxys Technology (FRA:5LB0) has a current LT-Debt-to-Total-Asset of 0.00. The current LT-Debt-to-Total-Asset is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is LT-Debt-to-Total-Asset calculated?
LT-Debt-to-Total-Asset is calculated from a company's financial statements. For BioVaxys Technology (FRA:5LB0), the current LT-Debt-to-Total-Asset is 0.00 as of Jul. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

BioVaxys Technology Business Description

Other Exchanges BVAXF:USABIOV:Canada
Address 595 Howe Street, Suite 303, Vancouver, BC, CAN, V6C 2T5
BioVaxys Technology Corp is a clinical-stage biopharmaceutical company dedicated to improving patient lives with novel immunotherapies based on the DPX immune-educating technology platform and its HapTenix 'neoantigen' tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization, and other immunological fields. The company's clinical stage pipeline includes maveropepimut-S which is in Phase II clinical development for Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant ovarian cancer, and BVX-0918, a personalized immunotherapeutic vaccine using its proprietary HapTenix 'neoantigen' tumor cell construct platform which is soon to enter Phase I in Spain for treating refractive late-stage ovarian cancer.